Clinical trial
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are…
NCT00093093 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00093093 |
|---|---|
| Title | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive |
| Official title | Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C |
| Acronym | VISER2 |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | Viramidine, Ribavirin, pegylated interferon alfa-2a |
| Enrollment | 900 |
| Start date | Jun 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Oct 4, 2004 |
| Last update posted | Jun 22, 2012 |
| Countries | Argentina, Australia, Canada, France, Israel, Italy, Poland, Puerto Rico, Russia, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: